Castle Biosciences, Inc. (CSTL) News
Track canonical SquawkNews coverage tagged to CSTL, Castle Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis
Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed int
LIVE | Sep 24, 2026, 08:32 PM UTC
L
CSTL - Castle Biosciences to Open New Laboratory Facility in Scottsdale
CSTL - Castle Biosciences to Open New Laboratory Facility in Scottsdale
NEWS | Sep 22, 2026, 11:01 AM UTC
L
CSTL: TissueCypher and melanoma test growth, AI integration, and regulatory advances drive expansion
Strong growth in molecular diagnostics, especially for TissueCypher, is supported by expanding sales teams and AI-driven technology. Regulatory progress and new evidence may drive future reimbursement and adoption, while
NEWS | Sep 15, 2026, 04:49 PM UTC
L
CSTL: TissueCypher and DecisionDx tests drive growth, with AI and reimbursement advances supporting expansion
Strong growth in molecular diagnostics, especially TissueCypher, is supported by robust margins and AI-driven innovation. Dermatology and gastroenterology segments are expanding, with new product launches and ongoing rei
NEWS | Sep 15, 2026, 04:19 PM UTC
L
CSTL: TissueCypher's rapid growth and AI-driven advances position the business for strong future expansion
Strong Q2 growth was driven by TissueCypher's 63% YoY volume increase and robust gross margins, with long-term market penetration modeled at 60%-65%. AI initiatives are enhancing test development and reimbursement, while
NEWS | Sep 15, 2026, 04:00 PM UTC
L
CSTL - New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
CSTL - New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
NEWS | Sep 15, 2026, 11:02 AM UTC
L
CSTL - JAAD Publication Shows Improved Performance of DecisionDx®-SCC
CSTL - JAAD Publication Shows Improved Performance of DecisionDx®-SCC
EQUITY | Sep 09, 2026, 08:30 PM UTC
L
SciBase receives additional order from Castle Biosciences
SciBase says it has received an additional order from Castle Biosciences to accelerate its ongoing clinical study and related preparations.
EQUITY | Sep 08, 2026, 01:32 PM UTC
L
CSTL - Castle Biosciences to Participate in Upcoming Investor Conferences
CSTL - Castle Biosciences to Participate in Upcoming Investor Conferences
EQUITY | Aug 20, 2026, 11:01 AM UTC
L
Castle Biosciences approved for dual listing on Nasdaq Texas
Castle Biosciences (CSTL) received approval for a dual listing on Nasdaq Texas, according to TradeXchange Newsdesk.
REGULATION | Aug 17, 2026, 11:00 AM UTC
L
CSTL posted a significant top-to-bottom-line beat in Q226 @ KEYB
CSTL posted a significant top-to-bottom-line beat in Q226 @ KEYB
EQUITY | Jul 31, 2026, 11:16 AM UTC
H
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:34 PM UTC
H
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after resu
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:18 PM UTC
L
Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est
Castle Biosciences (NASDAQ: CSTL ) raises FY2026 sales outlook from $345.000 million-$355.000 million to $365.000 million-$375.000 million vs $352.291 million estimate.
EARNINGS | Jul 30, 2026, 08:17 PM UTC
L
CSTL CSTL - Castle Biosciences Reports Second Quarter 2026 Results
CSTL CSTL - Castle Biosciences Reports Second Quarter 2026 Results
EARNINGS | Jul 30, 2026, 08:06 PM UTC
L
CSTL Castle Biosciences RESULTS: Q2, Q2 Operating Income $-3.07M, Q2 Net Income $-2.06M, Q2 REV $103.546M vs. EST $86.2M, Q2 operating expen
CSTL Castle Biosciences RESULTS: Q2, Q2 Operating Income $-3.07M, Q2 Net Income $-2.06M, Q2 REV $103.546M vs. EST $86.2M, Q2 operating expenses $106.616M, Q2 pretax profit $-1.69M
EARNINGS | Jul 30, 2026, 08:05 PM UTC
L
CSTL Castle Biosciences announces New York State department of health approval of its advancead-tx™ test
CSTL Castle Biosciences announces New York State department of health approval of its advancead-tx™ test
EQUITY | Jul 14, 2026, 08:30 PM UTC
M
CSTL Outperforms MIA
CSTL's DecisionDx-Melanoma's i31-SLNB outperforms MIA Nomogram in identifying patients who may safely forgo sentinel lymph node biopsy
EQUITY | Jun 25, 2026, 08:31 PM UTC
M
TNXP: Raymond James Initiates
Raymond James analyst initiates coverage on Tonix Pharmaceuticals with a Strong Buy rating and a price target of $26
EQUITY | Jun 25, 2026, 12:44 PM UTC
M
CSTL: Roth Initiates Buy
Roth Capital initiates coverage on Castle Biosciences with a Buy rating and a price target of $40
EQUITY | Jun 25, 2026, 10:39 AM UTC